Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health Investments (CLOV) saw an 8.53% increase in its stock price on Thursday, reaching $4.71 per share following Deutsche Bank's positive rating. The investment firm initially gave a "Buy" recommendation with a price target of $6, indicating a 27.4% potential upside from the previous closing price. This rating was driven by Clover Health's growth prospects in Medicare Advantage plans, their innovative Clover Assistant technology platform, and their non-delegated risk model.

The insurer reported a strong second quarter, posting a net income of $28 million after a $10.6 million loss in the same period last year, driven by a 48% increase in Medicare Advantage membership to 157,309. Total revenues expanded by 55.6% to $743.2 million compared to $477.6 million a year earlier. Clover Health adjusted its earnings guidance upwards, now projecting net income between $20 million and $35 million and revenues between $2.92 billion and $3 billion.

Institutional investors showed strong confidence, with a 375% increase in holdings for the quarter, as reported by Insider Monkey. While Clover Health is seen as a potential investment, the source suggests other AI stocks could offer greater upside with less risk.